Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-019 Phase 1/2 in Healthy Japanese Adults
NCT04712110Phase 2Completed
- Sponsor
- Takeda
- Start
- Feb 2021
- Primary completion
- Mar 2022
- Modality
- Recombinant Proteins and Enzymes, Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of NVX-CoV2373 in coronavirus disease 2019 (COVID-19), sponsored by Takeda. Started Feb 2021; status: completed.
02
Drugs
NVX-CoV2373
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04712110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04712110.